Medical equipment manufacturer Perkinelmer (NYSE: PKI) has pulled back in the past few months, following the rest of the market. However, there could be good news for investors of Perkinelmer as the stock hit two key support levels in the last week.
We see on the daily chart that the stock dropped down to its 104-week moving average at its low last week, but then bounced sharply from there. The stock did the same thing back in early 2017 before jumping approximately 40% in the next six months.
The second support level that jumped out at me was the $72.50 area. We see that the stock struggled to get above that price in late 2017 before breaking through in early 2018. The stock then moved sideways from February through June, but it never closed a week below the $72.50 level during that stretch. I look for that price area to serve as strong support and look for the stock to bounce in the coming months.
In addition to the technical support, Perkinelmer has strong fundamental indicators as well. The company has seen earnings grow by 13% per year over the last three years. In the most recent quarterly report earnings grew by 23% while sales grew by 22%.
Even with the technical support and strong fundamentals, investors and analysts aren’t very bullish on the stock. There are 14 analysts following the stock and only five of them rank the stock as a “buy”. This leaves room for upgrades that can help propel the stock higher.
The Moving Average Convergence Divergence (MACD) for RVTY turned positive on November 21, 2025. Looking at past instances where RVTY's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 20, 2025. You may want to consider a long position or call options on RVTY as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
RVTY moved above its 50-day moving average on November 07, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RVTY advanced for three days, in of 322 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 168 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for RVTY moved out of overbought territory on October 27, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RVTY broke above its upper Bollinger Band on November 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.511) is normal, around the industry mean (12.407). P/E Ratio (50.655) is within average values for comparable stocks, (134.795). Projected Growth (PEG Ratio) (0.641) is also within normal values, averaging (1.915). Dividend Yield (0.003) settles around the average of (0.016) among similar stocks. P/S Ratio (4.144) is also within normal values, averaging (9.817).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of analytical instruments
Industry MedicalSpecialties